Last reviewed · How we verify
alcaftadine 0.25% ophthalmic solution
Alcaftadine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses in the eye.
Alcaftadine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses in the eye. Used for Allergic conjunctivitis (itching associated with allergic conjunctivitis).
At a glance
| Generic name | alcaftadine 0.25% ophthalmic solution |
|---|---|
| Also known as | LASTACAFT® |
| Sponsor | Allergan |
| Drug class | Selective H1-receptor antagonist |
| Target | H1 histamine receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Alcaftadine works by competitively antagonizing H1 histamine receptors on mast cells and other immune cells in ocular tissues, preventing histamine release and reducing allergic inflammation. This mechanism provides rapid relief of itching and other allergic symptoms in allergic conjunctivitis. The drug's selectivity for H1 receptors and topical ocular delivery minimize systemic effects.
Approved indications
- Allergic conjunctivitis (itching associated with allergic conjunctivitis)
Common side effects
- Headache
- Ocular irritation
- Conjunctival hyperemia
- Eye discomfort
Key clinical trials
- Safety and Efficacy of Lastacaft® for the Prevention of Itching Associated With Allergic Conjunctivitis in Korea
- Safety and Efficacy Study of a Eye Drop for Eye Allergy (PHASE3)
- A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis (PHASE4)
- A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- alcaftadine 0.25% ophthalmic solution CI brief — competitive landscape report
- alcaftadine 0.25% ophthalmic solution updates RSS · CI watch RSS
- Allergan portfolio CI